CollPlant Biotechnologies Ltd. (CLGN)
NASDAQ: CLGN · Real-Time Price · USD
2.880
+0.110 (3.97%)
Aug 7, 2025, 4:00 PM - Market closed

Company Description

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally.

The company’s products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology.

It offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound healing flowable gel for the treatment of chronic and acute wounds.

The company also provides rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in various 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product.

It has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization.

The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019.

CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.

CollPlant Biotechnologies Ltd.
CollPlant Biotechnologies logo
CountryIsrael
Founded2004
IndustryBiotechnology
SectorHealthcare
Employees57
CEOYehiel Tal

Contact Details

Address:
Weizmann Science Park, 4 Oppenheimer
Rehovot, 7670104
Israel
Phone972 73 232 5600
Websitecollplant.com

Stock Details

Ticker SymbolCLGN
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001631487
CUSIP Number19516R107
ISIN NumberIL0004960188
SIC Code3842

Key Executives

NamePosition
Eran Rotem CPADeputy Chief Executive Officer and Chief Financial Officer
Yehiel TalChief Executive Officer and Director
Oren FahimipoorVice President of Operations
Dr. Elana GazalVice President of Research and Development
Prof. Oded ShoseyovFounder and Chief Scientist
Hadas Dreiher HorowitzVice President of Human Resources

Latest SEC Filings

DateTypeTitle
Jul 14, 20256-KReport of foreign issuer
Jul 3, 2025EFFECTNotice of Effectiveness
Jul 3, 2025424B3Prospectus
Jun 30, 2025UPLOADFiling
Jun 17, 2025F-1Registration statement for certain foreign private issuers
Jun 9, 20256-KReport of foreign issuer
Jun 4, 20256-KReport of foreign issuer
Jun 4, 2025DNotice of Exempt Offering of Securities
Jun 2, 2025424B5Filing
Jun 2, 20256-KReport of foreign issuer